Literature DB >> 25288417

Specialty medications: traditional and novel tools can address rising spending on these costly drugs.

Alan M Lotvin1, William H Shrank2, Surya C Singh3, Benjamin P Falit4, Troyen A Brennan5.   

Abstract

Spending on specialty medications, which represented a small proportion of US pharmacy spending at the beginning of this decade, is growing by more than 15 percent annually. It is expected to account for approximately half ($235 billion) of total annual pharmacy spending by 2018. Among the numerous reasons for the high cost of this heterogeneous group of medications are the increasing size of target patient populations, the high cost of drug development, and a complex and uncoordinated delivery system. In this article we describe the evolution of the specialty market, characterize the current state of specialty medication use, and articulate key challenges and potential solutions. Fully realizing the potential value of the expanding universe of specialty medications will require collaborative efforts to reduce waste and promote value. Those who prescribe, dispense, deliver, and pay for specialty medications will need to employ a combination of traditional and novel management approaches, such as prior authorization, step therapy, tiered formularies, administration at lower-cost sites, and the unique tools being developed for cancer medications. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Cost of Health Care; Health Spending; Managed Care; Pharmaceuticals

Mesh:

Substances:

Year:  2014        PMID: 25288417     DOI: 10.1377/hlthaff.2014.0511

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.

Authors:  Stacie B Dusetzina; Nancy L Keating
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

2.  The Present and the Future of Cost-Related Non-Adherence in Medicare Part D.

Authors:  William H Shrank; Jennifer M Polinski
Journal:  J Gen Intern Med       Date:  2015-08       Impact factor: 5.128

3.  Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.

Authors:  Aaron N Winn; Nancy L Keating; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.

Authors:  Hannah Song; Adewole Adamson; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

5.  DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.

Authors:  Brandy Henry
Journal:  J Health Biomed Law       Date:  2018-09

6.  Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Authors:  Adam J Olszewski; Stacie B Dusetzina; Charles B Eaton; Amy J Davidoff; Amal N Trivedi
Journal:  J Clin Oncol       Date:  2017-05-25       Impact factor: 50.717

7.  Quality Improvement Project to Reduce Drug-Related Problems (DRPs) and Potentially Inappropriate Medications (PIMs) in Geriatrics Cardiac Clinic in Saudi Arabia.

Authors:  Sanaa S Mekdad; Alaa A Alsayed
Journal:  Can Geriatr J       Date:  2019-06-30

8.  Branded prescription drug spending: a framework to evaluate policy options.

Authors:  Jeromie Ballreich; G Caleb Alexander; Mariana Socal; Taruja Karmarkar; Gerard Anderson
Journal:  J Pharm Policy Pract       Date:  2017-10-02

9.  Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.

Authors:  Alexandra Erath; Stacie B Dusetzina
Journal:  JAMA Netw Open       Date:  2020-04-01

10.  The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.

Authors:  Kristina F Simacek; John J Ko; Debbie Moreton; Stefan Varga; Kristen Johnson; Bozena J Katic
Journal:  J Med Internet Res       Date:  2018-10-30       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.